未来对基于模型的精确剂量测定工具进行验证,用于治疗新生儿的万科米辛
Riste Kalamees1, Hiie Soeorg1, Mari-Liis Ilmoja2
1Department of Microbiology, University of Tartu, Tartu, Estonia.
Antimicrobial agents and chemotherapy
|April 5, 2024
概括
基于模型的精确剂量软件改善了在新生儿中达到万科米辛度目标的效果. 这种精确剂量方法提高了治疗药物监测的有效性,而不会增加不良事件.
科学领域:
- 新生儿药理学 新生儿药理学
- 药理动力学/药理动力学建模
- 传染病治疗 传染病治疗
背景情况:
- 范科米对于治疗新生儿感染至关重要.
- 在新生儿中,达到康胺度的目标是具有挑战性的.
- 目前的剂量策略在优化治疗结果方面存在局限性.
研究的目的:
- 为了验证一种基于模型的精确剂量 (MIPD) 软件对新生儿的万科米辛.
- 评估MIPD对达到康素目标最低度的影响.
- 与标准护理相比,评估MIPD的安全概况.
主要方法:
- 一项前性研究,涉及48名新生儿 (50次治疗).
- 使用基于人口药理动力学模型的MIPD软件来给定万科米辛剂量.
- 每36-48小时进行一次剂量调整.
- 结果与历史对照组 (53名新生儿,65次发作) 进行了比较.
主要成果:
- 在62%的发作中,MIPD组实现了康素最低度 (10-15 mg/L) 的目标.
- 这与历史对照组的37% (P = 0.01) 相比,是一个显著的改善.
- 两组之间没有观察到副作用发生率的显著差异.
结论:
- 基于模型的精确剂量软件有效地改善了新生儿的万科米辛度目标.
- 在新生儿群体中,MIPD为优化万科米辛治疗提供了一个有希望的策略.
- 经过验证的MIPD方法增强了治疗药物监测,而不会影响安全.
相关概念视频
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Estimation of k and VD of Aminoglycosides
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


